General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1086 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-27

Study Completion Date

2025-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general decolonization of the human body surface by industrial antiseptic agents, before elective surgery is recommended by the World Health Organization (WHO).

A specific randomized-controlled trial specifically among high-risk adult orthopedic patients for infection has not been performed.

In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision surgery and surgical site infections

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

NCT03385304

Surgical Site Infection Unplanned Fracture-Related Reoperation Open Appendicular Fracture

COMPLETED PHASE4

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

NCT06378359

Staphylococcus Aureus Colonization Surgical Site Infections Healthcare Associated Infections

RECRUITING

Chlorhexidine and/or Betadine Prep in Pediatric Arm Surgery Following Trauma

NCT04225065

Arm Fracture Surgical Site Infection

TERMINATED NA

Does Disinfection of the Subcutaneous Tissue Reduce Contamination of the Operating Field With P. Acnes?

NCT04250649

Surgical Incision

UNKNOWN NA

Does the Disinfection of the Subcutaneous Tissue Reduce the Contamination of the Operative Field by P. Acnes During Primary Shoulder Surgery?

NCT03664284

Shoulder Surgery

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The general decolonization of the human body surface and, of adjacent pathogen reservoirs such as the nose, by industrial antiseptic agents by the World Health Organization (WHO) for the risk reduction of superficial and deep surgical site infection (SSI). Such a decolonization is regarded as evidence-based in the majority of randomized, and before-after trials, since two decades, although negative studies also exist.

In the orthopedic field, this decolonization is likely to be more effective in elective patients with a proven body colonization of Staphylococcus aureus. The decolonization might be equally efeective in orthopedic patients with an inherent high risk for SSI, for which the majority of future SSI pathogens are skin commensals and S. aureus. These (eventual and future) pathogens of SSI are accessible to the topical agents during the index surgery, if the patients are well instructed and know how to decolonize themselves.

In contrast, this pre-surgical decolonization is only a supplementary measure in the bundle of all combined efforts to prevent revision surgery for infection. Its individual power is limited for young, healthy individuals, for SSIs caused by pathogens from the internal body sites (intestinal, urinary, gynecologic regions), infections acquired on the surgical ward, and in settings with less specialized surgeries and a low volume of surgical experience. Hence, in trials including all patients (or only those carrying S. aureus), the beneficial effect of decolonization can be diluted and provoke an additional costly and cumber-some organizational procedure for the majority of patients with low to moderate SSI risks.

Moreover, many surgical site infections in orthopedic surgery, especially in implant-related surgery, are more due to coagulase-negative staphylococci (CoNS) than for S. aureus.

The hallmark of the CoNS group is S. epidermidis with approximatively 70% resistance (in Switzerland) to standard prophylactic antibiotic agents9, As S. epidermidis is part of the normal human flora, typically the skin flora, and, only becomes pathogenic under certain conditions, a screening for this microorganism is not feasible in common practice,. while the prophylaxis-resistant part of all orthopedic SSI pathogens is at 30-50%.

In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision sur-gery and SSI; inde-pendently of a known body carriage for S. aureus.

This study will be performed with an existing "set" manufactured by Schülke \& Mayr GmbH. The "Set" was placed on the market in 2016. The distribution of Octenisan® wash lotion and Octenisan® nasal gel in the form of a set (Octenisan® Set) largely streamlines and facilitates the organizational application and compliance efforts of the study.

Academically and clinically, we will gain insight in the performance of decolonization for a patient population at particular risk of postoperative complications, where every effort to prevent infection is of importance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elective Surgery High Risk Prevention of Surgical Site Infections Randomized-controlled Trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-Center, Unblinded, Superiority, Randomized-Controlled Trial (Randomization 1:1)

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Decolonization

This study will be performed with an existing "set" manufactured by Schülke \& Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance.

The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery.

During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization.

Group Type EXPERIMENTAL

Whole Body and nasal decolonization with octenidin (Octenisan Set)

Intervention Type DRUG

Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.

Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period

Questionnaire for study participants immediately after the decolonization

Intervention Type BEHAVIORAL

A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).

The questionnaire is handmade and validated by the Investigators.

Non-Decolonization

No Decolonization preoperatively

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole Body and nasal decolonization with octenidin (Octenisan Set)

Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.

Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period

Intervention Type DRUG

Questionnaire for study participants immediately after the decolonization

A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).

The questionnaire is handmade and validated by the Investigators.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patients with an age ≥ 80 years (as considered particularly at risk for SSI)
* Elective orthopedic surgery at the Balgrist
* Chronic immune-suppression (diabetes mellitus, active cancer, cirrhosis CHILD C, renal dialysis, untreated HIV disease, medicamentous immune-suppression equivalent to prednisone ≥ 10 mg/day)
* Elective surgery in ischemic skin (e.g. major amputations)
* Elective surgery on non-diabetic and non-infected ulcerated skin
* Tumor (oncologic) orthopedic surgery
* ASA-Scores 3-4 points

Exclusion Criteria

* Elective revision orthopedic surgery due to orthopedic infection within the last 12 months in the same area of surgery
* Emergency surgery (defined as planned surgery within the next 48 hours)
* Surgery on infected skin; or surgery under antibiotic treatment for any reason
* "Diabetic foot surgery" (distinct clinical entity; defined as below the ankle)
* Body mass index ≥ 35 kg/m2 (anticipated difficulty of effective decolonization)
* Pregnancy (formality reasons)
* Intolerance or allergy to octenidin and/or ingredients in the Octenisan® set
* Use of any other topical antiseptic agents other than Octenisan® set (except for the duration of one day)
* Patient unable to understand; or under legal guardian for medical decisions
* Anticipated clinical follow-up of less than 6 weeks after surgery.
* ASA-Scores 1-2, and ASA-Score 5 (high risk of postoperative complications)
* Known skin colonization with antibiotic-multiresistant Gram-negative organisms defined by infection control protocols of Switzerland1

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No